Inhibrx CEO Mark Lappe buys over $848k in company stock
Inhibrx CEO Mark Lappe purchased over $848,976 worth of company stock on October 14, 2026. He acquired 10,040 shares through various trusts, with prices between $83.61 and $85.62 per share. The current trade price is $85.26, indicating a 145% return on investment over the past year. However, InvestingPro analysts deem the stock overvalued.
Mr. Lappe, trustee for the Lappe Family Trust, and as a family member, indirectly holds 745,588 shares from these transactions and an additional 170,000 shares through the Descendants' Trust. Inhibrx reported positive Phase 2 trial results for its drug INBRX-106 in combination with pembrolizumab, showing a 48.3% objective response rate compared to 26.5% with pembrolizumab alone.
Both H.C. Wainwright and Stifel maintained Buy ratings with respective price targets, while Citizens opted for Market Perform. The company continues to generate interest among analysts, despite mixed opinions on its future potential.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
Also reported by 1 other outlet
- Paysign CEO Mark Newcomer sells $766,895 of PAYS stock investing.com
